Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )
ClinicalTrials.gov Identifier:
NCT00316888
First received: April 19, 2006
Last updated: July 18, 2016
Last verified: July 2016
  Purpose

RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Cetuximab may help cisplatin and fluorouracil work better by making tumor cells more sensitive to the drugs. It may also make tumor cells more sensitive to radiation therapy. Giving cetuximab together with chemotherapy and radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving cetuximab together with cisplatin, fluorouracil, and radiation therapy works in treating immunocompetent patients with stage I (closed to accrual as of 11/3/2008), stage II, (some stage II closed to accrual as of 11/3/2008) or stage III anal cancer.


Condition Intervention Phase
Anal Cancer
Biological: cetuximab
Drug: cisplatin
Drug: fluorouracil
Radiation: radiotherapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma

Resource links provided by NLM:


Further study details as provided by Eastern Cooperative Oncology Group:

Primary Outcome Measures:
  • Local Failure Rate at 3 Years [ Time Frame: assessed every 3 months for patients within 2 years of registration, then every 6 months for patients in year 3 (ie, one assessment at 2.5 years and one at 3 years after registration) ] [ Designated as safety issue: No ]
    Local failure was defined as progression/relapse of disease in the anal canal and/or regional organs and/or regional lymph nodes after completion of protocol therapy, or progression during protocol therapy. Lost to follow-up and death (regardless of cause of death) prior to 3 years were also considered as local failures. For the calculation of local failure rate at 3 years, patients were classified into two groups (ie, coded as binary variable): failure (patients with local failure events prior to 3 years) vs. no failure (patients who still alive and had no local failure at 3 years). The binomial proportion and its exact two-sided 80% confidence interval (CI) were used to estimate it.


Secondary Outcome Measures:
  • 3-year Overall Survival Rate [ Time Frame: assessed every 3 months for patients within 2 years of registration, every 6 months for patients 3-5 years from registration and yearly for patients 5-10 years from registration ] [ Designated as safety issue: No ]
    Overall survival (OS) is defined as time from registration to death from any cause. Patients alive are censored at the last contact date. Kaplan-Meier method was used to estimate the 3-year OS rate.

  • 3-year Progression-free Survival Rate [ Time Frame: assessed every 3 months for patients within 2 years of registration, every 6 months for patients 3-5 years from registration and yearly for patients 5-10 years from registration ] [ Designated as safety issue: No ]
    Progression-free survival (PFS) was defined as time from registration to disease progression, relapse or death (whichever occurred first), censoring cases without PFS events at the date of last disease assessment documenting the patient was free of progression/relapse. Kaplan-Meier method was used to estimate the 3-year PFS rate

  • Objective Response Rate [ Time Frame: Tumor assessments were made at baseline, within 4 weeks of the completion of protocol treatment, then every 6 months if patient was 1-4 years from registration, yearly if patient was 5-10 years from registration until progression/relapse using the RECIST ] [ Designated as safety issue: No ]
    Objective response rate is defined as number of patients with complete response (CR) or partial response (PR) divided by all eligible and treated patients. Responses are evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline. CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameters), and/or persistence of one or more non-target lesion(s).

  • 3-year Colostomy-free Survival Rate [ Time Frame: assessed every 3 months for patients within 2 years of registration, every 6 months for patients 3-5 years from registration and yearly for patients 5-10 years from registration ] [ Designated as safety issue: No ]
    Colostomy-free survival was defined as time from registration until time of colostomy or death without colostomy, censoring cases without colostomy at the data of last disease assessment documenting the patient was free of colostomy. Kaplan-Meier method was used to estimate the 3-year colostomy-free survival rate.


Enrollment: 63
Study Start Date: January 2007
Estimated Study Completion Date: May 2022
Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (closed to accrual as of 11/3/2008)
Patients receive cisplatin IV over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57. Treatment continues in the absence of disease progression or unacceptable toxicity.
Biological: cetuximab
Given IV
Other Name: Erbitux
Drug: cisplatin
Given IV
Other Names:
  • Cis-diaminedichloroplatinum Cis-diaminedichloroplatinum (II)
  • Platinol
  • Platinol-AQ
  • cis-platinum
  • diaminedichloroplatinum
  • DDP
Drug: fluorouracil
Given IV
Other Names:
  • 5-Fluorouracil
  • 5-FU
  • Adrucil
  • Efudex
Radiation: radiotherapy
Given once daily 5 days a week for 5 weeks
Other Name: radiation therapy
Experimental: Arm II (open to accrual on 8/18/2009)
Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 1 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
Biological: cetuximab
Given IV
Other Name: Erbitux
Drug: cisplatin
Given IV
Other Names:
  • Cis-diaminedichloroplatinum Cis-diaminedichloroplatinum (II)
  • Platinol
  • Platinol-AQ
  • cis-platinum
  • diaminedichloroplatinum
  • DDP
Drug: fluorouracil
Given IV
Other Names:
  • 5-Fluorouracil
  • 5-FU
  • Adrucil
  • Efudex
Radiation: radiotherapy
Given once daily 5 days a week for 5 weeks
Other Name: radiation therapy

Detailed Description:

OBJECTIVES:

Primary Objective:

  • Determine whether the addition of cetuximab to combined modality therapy (CMT) comprising cisplatin, fluorouracil, and radiotherapy reduces the local failure rate by ≥ 50% at 3 years (compared with historical data) in immunocompetent patients with stage I-III invasive anal carcinoma.

Secondary Objectives:

  • Determine objective response rate (complete and partial), progression-free survival, colostomy-free survival, and overall survival.
  • Determine the overall toxicity of concurrent cisplatin, fluorouracil, and radiation therapy combined with cetuximab.

Exploratory Objectives:

  • Evaluate the effect of cetuximab and CMT on anogenital herpes papilloma virus (HPV) infection and anal cytology.
  • Evaluate whether moderate to strong expression of epidermal growth factor receptor, Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), and P-Akt (as determined by immunohistochemistry) is associated with an increased risk of local failure.

OUTLINE: This is a multicenter study with two sequential arms. Arm I was closed to accrual as of 11/3/2008, and arm II opened to accrual on 8/18/2009. Patients are assigned to 1 of the 2 treatment arms.

  • Arm I (closed to accrual as of 11/3/2008): Patients receive cisplatin intravenously (IV) over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57.
  • Arm II (open to accrual on 8/18/2009): Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 8 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8.

After completion of study treatment, patients are followed periodically for up to 10 years.

PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  • Histologically confirmed anal canal or perianal (anal margin) squamous cell carcinoma

    • Stage I-IIIB (closed to accrual as of 11/3/2008)
    • Stage II (T3, N0 only), IIIA, or IIIB
    • Tumors of nonkeratinizing histology, such as basaloid, transitional cell, or cloacogenic histology, allowed
    • No well-differentiated stage I anal margin cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Hemoglobin ≥ 10 g/dL
  • Platelet count ≥ 100,000/mm^3
  • Absolute neutrophil count > 1,500/mm^3
  • Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance > 60 mL/min
  • Bilirubin ≤ 2 times ULN
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times ULN
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
  • No other malignancies except nonmelanomatous skin cancer

    • Prior malignancies must be in remission for ≥ 5 years
  • Patients with a known risk factor for human immunodeficiency virus (HIV) infection must undergo HIV testing within 90 days before study entry AND must be HIV negative by antibody detection, culture, or quantitative assay of plasma HIV ribonucleic acid (RNA)

EXCLUSION CRITERIA:

  • Presence of the following conditions within the past 6 months:

    • Active infection
    • Uncontrolled diabetes
    • New York Heart Association class II-IV congestive heart failure
    • Cerebrovascular accident
    • Transient ischemic attack
    • Uncontrolled hypertension
    • Unstable angina
    • Myocardial infarction
  • History of rheumatic disorders, irritable bowel syndrome, or inflammatory bowel disease
  • Known HIV positivity
  • Known risk factors for HIV infection
  • Prior radiotherapy or chemotherapy for this malignancy
  • Prior pelvic radiotherapy
  • Prior potentially curative surgery (i.e., abdominal or peritoneal resection) for anal cancer
  • Pregnant or nursing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00316888

  Show 125 Study Locations
Sponsors and Collaborators
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
Investigators
Study Chair: Madhur K. Garg, MD Montefiore Medical Center
Study Chair: Joseph A. Sparano, MD Montefiore Medical Center
  More Information

Publications:
Garg M, Lee JY, Kachnic LA, et al.: Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results. [Abstract] J Clin Oncol 30 (Suppl 15): A-4030, 2012.

Responsible Party: ECOG-ACRIN Cancer Research Group
ClinicalTrials.gov Identifier: NCT00316888     History of Changes
Other Study ID Numbers: E3205  E3205  U10CA023318  CDR0000470269 
Study First Received: April 19, 2006
Results First Received: July 18, 2016
Last Updated: July 18, 2016
Health Authority: United States: Food and Drug Administration
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.

Keywords provided by Eastern Cooperative Oncology Group:
squamous cell carcinoma of the anus
stage I anal cancer
stage II anal cancer
stage IIIA anal cancer
stage IIIB anal cancer
basaloid carcinoma of the anus
cloacogenic carcinoma of the anus

Additional relevant MeSH terms:
Anus Neoplasms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anus Diseases
Rectal Diseases
Cisplatin
Fluorouracil
Cetuximab
Antineoplastic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 26, 2016